Skip to content
Screener

Bristol-Myers Squibb BMY Q4 2025 Annual earnings

Reported February 5, 2026 · Before market open

Revenue$12.5BBeat by $221.7M
EPS$1.26Beat by $0.03
Revenue estimate$12.3B
EPS estimate$1.23

Next report

Oct 29, 2026 (In 3 weeks)
Revenue estimate$12.6B
EPS estimate$1.68

Financials

Q4 2025

Income statement

See full
Revenue$12.5B+1.3%
Gross profit$8.4B+11.6%
Net income$1.1B—
EPS (diluted)$0.53—

Balance sheet

See full
Cash & equivalents$10.2B-1.3%
Total debt$47.1B-7.9%
Total equity$18.5B+13.1%
Total assets$90.0B-2.8%

Cash flow

See full
Operating cash flow$2.0B-55.5%
CapEx$370.0M-2.1%
Free cash flow$1.6B-60.5%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$109.81B-4.3%
Enterprise value$146.74B-5.7%
P/E15.6×—
P/S2.3×-0.1×

Profitability

See full
Gross margin71.1%0.0pp
Net margin14.6%+9.4pp
FCF margin26.7%-2.2pp

Returns & leverage

See full
Return on equity40.5%+27.1pp
Debt / equity2.6×-0.6×
Current ratio1.3×0.0×

Segments

By product

See full
Eliquis$3.5B+8.0%
Opdivo$2.7B+8.6%
Orencia$1.0B+0.8%
Yervoy$810.0M+20.0%
Pomalyst/Imnovid$692.0M-15.9%

FAQ

When did Bristol-Myers Squibb report Q4 2025 earnings?
Bristol-Myers Squibb (BMY) reported Q4 2025 earnings on February 5, 2026 before market open.
What were Bristol-Myers Squibb's Q4 2025 revenue and EPS?
Bristol-Myers Squibb reported revenue of $12.5B and eps of $1.26 for Q4 2025.
Did Bristol-Myers Squibb beat estimates in Q4 2025?
Revenue beat the consensus estimate of $12.3B by $221.7M. EPS beat the consensus estimate of $1.23 by $0.03.
How did Bristol-Myers Squibb's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 1.3% from $12.3B a year earlier and eps declined 24.6% from $1.67.
Where can I find Bristol-Myers Squibb's Q4 2025 SEC filings?
You can read the 8-K earnings release (0000014272-26-000002) and the 10-K periodic report (0000014272-26-000004) directly on SEC EDGAR. The filing index links above go to sec.gov.